Prescription-Event Monitoring (PEM): The Evolution to the New Modified PEM and its Support of Risk Management

Mann's Pharmacovigilance: Third Edition

Volumn , Issue , 2014, Pages 359-384

  Layton, Deborah ^a,b   Shakir, Saad ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Frequency rates of adverse events; Intensive monitoring; Nationwide datasets; Observational cohort studies; Pharmacovigilance in New Zealand; Prescription event monitoring; Signal identification; Utilization studies

Indexed keywords

EID: 84926512925     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118820186.ch22     Document Type: Chapter

References (66)

1. Acharya, N.V., Pickering, R.M., Wilton, L.W., & Shakir, S.A. (2005) The safety and effectiveness of newer antiepileptics: a comparative postmarketing cohort study. J Clin Pharmacol, 45 (4), 385-393.
2. Anon. (1986) Medicines (Adverse Reactions). Hansard 90(c620W).
3. Aurich-Barrera, B., Wilton, L.V., & Shakir, S.A. (2009) Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study. Drug Saf, 32 (1), 43-54.
4. Beardon, P.H., McGilchrist, M.M., McKendrick, A.D. et al. (1993) Primary non-compliance with pre-scribed medication in primary care. BMJ, 307 (6908), 846-848.
5. BMA (2006) Reporting Adverse Drug Reactions. A Guide for Healthcare Professionals. British Medical Association Board of Science, British Medical Association Science & Education, London. URL http://bmaopac.hosted.exlibrisgroup.com/exlibris/aleph/a21_1/apache_media/GYVFNJ1RT2PFNDUJ8IUKPUNTFVRF8G.pdf [accessed on 10 December 2013].
6. Boshier, A., Wilton, L.V., & Shakir, S.A. (2003) Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol, 59 (10), 767-773.
7. Boshier, A., Wilton, L.V., & Shakir, S.A. (2004) Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU Int, 93 (6), 796-801.
8. Buggy, Y., Cornelius, V., Wilton, L., & Shakir, S.A. (2011) Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England. Drug Saf, 34 (6), 501-509.
9. Buggy, Y., Cornelius, V., Fogg, C. et al. (2013) Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice. Drug Saf, 36 (7), 521-531.
10. CIOMS & WHO (2002) International Ethical Guidelines for Biomedical Research Involving Human Subjects. Council for International Organizations of Medical Sciences(CIOMS) and World Health Organization (WHO), Geneva. URL http://www.cioms.ch/publications/layout_guide2002.pdf [accessed on 10 December 2013].
11. Davies, M.N., Paiba, N., Wilton, L.W., & Shakir, S.A.W. (2007) A 12 month modified prescription-event monitoring report for travoprost. Drug Saf, 30 (10), 919-990 (abstract P.020).
12. Davies, M., Tong, E., Fogg, C. et al. (2010) Atomoxetine end of modified PEM study report. Drug Safety Research Unit, Southampton.
13. Davies, M., Wilton, L., & Shakir, S. (2013) Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study. Drug Saf, 36 (4), 237-246.
14. Doe, C., Fogg, C., Layton, D., & Shakir, S.A.W. (2010) Interim results of a modified prescription event monitoring study on ivabradine: case series of utilisation in patients under the age of 40 years. Pharmacoepidemiol Drug Saf, 19 (Suppl. 1), abstract 330.
15. DOH (2000) Supplementary operational guidelines for NHS research ethics committees - November 2000. Multi-centre research in the NHS - the process of ethical review when there is no local researcher. Department of Health. URL http://webarchive.nationalarchives.gov.uk/20130107105354/[accessed 10 December 2013].
16. DSRU (2013) Studies in Secondary Care. URL: http://www.dsru.org/studies-for-risk-management/studies-in-specialist-hospital-care [accessed 23 January 2014].
17. Dunn, N., Wilton, L.V., Pearce, G., & Mann, R.D. (1997) The incidence of hallucinations associated with tramadol. Pharmacoepidemiol Drug Saf, 6 (Suppl. 2), abstract 042.
18. EMA (2012) Guideline on good pharmacovigilance practices. Module VIII -Post-authorisation studies, EMA/330405/2012, European Medicines Agency. URL http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129137.pdf Date [accessed on 20 July 2012].
19. EMA (n.d.) Good pharmacovigilance practices. URL http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp [accessed on 23 December 2013].
20. ENCePP (2013) ENCePP E-Register of Studies. DSRU. An observational post-authorisation safety specialist cohort monitoring study (SCEM) to monitor the safety and utilisation of asenapine (Sycrest™) in the mental health trust setting in England. URL: http://www.encepp.eu/encepp/studiesDatabase.jsp.
21. ENCePP (n.d.a) ENCePP E-Register of Studies. DSRU. An observational post-authorization modified prescription-event monitoring safety study to monitor the safety and utilization of exenatide once weekly (Bydureon™) in the primary care setting in England. URL http://www.encepp.eu/encepp./studiesDatabase.jsp.
22. ENCePP (n.d.b) ENCePP E-Register of Studies. DSRU. An observational post-authorization modified prescription-event monitoring safety study to monitor the safety and utilization of asenapine (Sycrest™) in the primary care setting in England. URL http://www.encepp.eu/encepp./studiesDatabase.jsp.
23. ENCePP (n.d.c) ENCePP E-Register of Studies. DSRU. An observational post-authorization modified prescription-event monitoring safety study to monitor the safety and utilization of rivaroxaban (Xarelto™) in the primary care setting in England. URL http://www.encepp.eu/encepp./studiesDatabase.jsp.
24. ENCEPP (n.d.d). ENCePP E-register of Studies. DSRU. An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (XareltoTM) for the Prevention of Stroke in Patients with AF, Treatment of DVT and PE, and the Prevention of Recurrent DVT and PE in the Secondary Care Hospital Setting in England and Wales. URL http://www.encepp.eu/encepp/studiesDatabase.jsp
25. ENCEPP (n.d.e). ENCePP E-register of Studies. DSRU. Modified Prescription-Event-Monitoring Study on Extended-Release Quetiapine (Seroquel XL™). URL http://www.encepp.eu/encepp/studiesDatabase.jsp
26. ENCEPP (n.d.f). ENCePP E-register of Studies. DSRU. Observational Assessment of Safety in Seroquel (OASIS) Study. URL http://www.encepp.eu/encepp/studiesDatabase.jsp
27. Farrington, C.P., Nash, J., & Miller, E. (1996) Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol, 143 (11), 1165-1173.
28. Flanders, W.D. & Louv, W.C. (1986) The exposure odds ratio in nested case-control studies with competing risks. Am J Epidemiol, 124 (4), 684-692.
29. Freemantle, S.N., Pearce, G.L., Wilton, L.W. et al. (1997) The incidence of the most commonly reported events with 40 newly marketed drugs - study by prescription-event monitoring. Pharmacoepidemiol Drug Saf, 6 (Suppl. 1), 1-8.
30. GMC (2013) Good Medical Practice. General Medical Council. URL http://www.gmc-uk.org/Prescribing_Guidance:_2013__50955425.pdf [accessed on 23 December 2013].
31. Hazell, L. & Shakir, S.A. (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf, 29 (5), 385-396.
32. Health Research Authority (n.d.) Confidentiality Advisory Group advice and approval decisions. Prescription-event monitoring, CAG ref: ECC 5-07(b)/2009. URL: http://www.hra.nhs.uk/about-the-hra/our-committees/section-251/cag-advice-and-approval-decisions/[accessed on 23 December 2013].
33. Heeley, E., Riley, J., Layton, D. et al. (2001) Prescription-event monitoring and reporting of adverse drug reactions. Lancet, 358 (9296), 1872-1873.
34. ICH (2003) ICH Harmonised Tripartite Guideline. Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting E2D. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva.
35. Kasliwal, R., Layton, D., Harris, S. et al. (2005) A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data. Drug Saf, 28 (9), 803-816.
36. Kasliwal, R., Cornelius, V., Wilton, L.W., & Shakir, S.A.W. (2008) Combined pioglitazone-insulin use: analysis from the pioglitazone PEM study. Pharmacoepidemiol Drug Saf, 17 (Suppl. 1), abstract 255.
37. Kasliwal, R., Wilton, L.V., & Shakir, S.A. (2009) Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf, 32 (6), 499-507.
38. Key, C., Layton, D., & Shakir, S.A. (2002) Results of a postal survey of the reasons for non-response by doctors in a prescription event monitoring study of drug safety. Pharmacoepidemiol Drug Saf, 11 (2), 143-148.
39. Layton, D. & Shakir, S.A.W. (2011) Prescription-event monitoring. In: B.L. Strom, S.E. Kimmel, & S. Hennessy (eds), Pharmacoepidemiology, 5 edn, pp. 301-330. John Wiley & Sons, Ltd, Chichester.
40. Layton, D., Clark, D.W., Pearce, G.L., & Shakir, S.A. (2001) Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol, 57 (2), 167-176.
41. Layton, D., Heeley, E., & Shakir, S.A.W. (2004) Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using prescription-event monitoring (PEM) data. J Clin Pharm Ther, 29 (2) 171-181.
42. Layton, D., Wilton, L., Boshier, A. et al. (2006) Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf, 29 (10), 897-909.
43. Layton, D., Wilton, L., & Shakir, S.A. (2009) Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf, 32 (2), 169-179.
44. Layton, D., Osborne, V., Al-Shukri, M., & Shakir, S.A.W. (2011) Indicators of dependence and aberrant behaviours during post-marketing use of fentanyl buccal tablets: risk scores in support of risk management [abstract OP22]. In: 11th Annual Conference of the International Society of Pharmacovigilance (ISOP), 26-28 October, Istanbul, Turkey.
45. Layton, D., Davies, M., Evans, A., & Shakir, S.A.W. (2013) Methodological considerations in evaluating the safety of novel anticoagulants in secondary care setting in the UK: defining the contextual comparator cohort. Pharmacoepidemiol Drug Saf, 22 (Suppl. 1), abstract 216.
46. Machin, D., Campbell, M., Fayers, P. & Pinol, A. (1997) Sample Size Tables for Clinical Studies. Blackwell Science, Ltd, Oxford.
47. Mackay, F.J. (1998) Post-marketing studies: the work of the Drug Safety Research Unit. Drug Saf, 19 (5), 343-353.
48. Mackay, F.J., Wilton, L.V., Pearce, G.L. et al. (1997) Safety of long-term lamotrigine in epilepsy. Epilepsia, 38 (8), 881-886.
49. Martin, R.M., Biswas, P., & Mann, R.D. (2000) The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br J Clin Pharmacol, 50 (1), 35-42.
50. Osborne, V., Layton, D., Perrio, M. et al. (2010) Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England. Drug Saf, 33 (7), 579-591.
51. Osborne, V., Layton, D., Tong, E., & Shakir, S.A.W. (2011) Safety of Atrovent® CFC-free MDI (metered dose inhaler): an example of protopathic bias in observational cohort studies. Pharmacoepidemiol Drug Saf, 20 (Suppl. 1), abstract 305.
52. Osborne, V., Al-Shukri, M., Gilchrist, A. et al. (2013) A modified prescription event monitoring study on fentanyl pectin nasal spray (PecFent®) for the management of breakthrough cancer pain. Final Study Report. Drug Safety Research Unit, Southampton.
53. Osborne, V., Layton, D., Fogg, C. et al. (2013) Utilisation of fentanyl buccal tablets in England: exploring off-label use reported in a cohort study. Eur J Pain, in press. doi: 10.1002/j.1532-2149.2013.00389.x.
54. Pearce, H.M., Layton, D., Wilton, L.V., & Shakir, S.A. (2005) Deep vein thrombosis and pulmonary embolism reported in the prescription event monitoring study of Yasmin. Br J Clin Pharmacol, 60 (1), 98-102.
55. Perrio, M.J., Wilton, L.V., & Shakir, S.A. (2007) A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring. Pharmacoepidemiol Drug Saf, 16 (9), 969-978.
56. Petri, H. & Urquhart, J. (1991) Channeling bias in the interpretation of drug effects. Stat Med, 10 (4), 577-581.
57. Ray, W.A. (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol, 158 (9), 915-920.
58. RCP (1996) Guidelines on the Practice of Ethical Committees in Medical Research involving Human Subjects. Royal College of Physicians of London.
59. Shakir, S.A., Wilton, L.V., Boshier, A. et al. (2001) Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ, 322 (7287), 651-652.
60. Strom, B. (1994) Sample size considerations for pharmacoepidemiology studies. In: B. Strom (ed.), Pharmacoepidemiology, 2nd edn. John Wiley & Sons, Ltd, Chichester.
61. Vlckova, V., Cornelius, V., Kasliwal, R. et al. (2009) Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf, 32 (5), 409-418.
62. Willemen, M., Mantel-Teeuwisse, A.K., Buggy, Y. et al. (2012) Reasons for and time to discontinuation of rimonabant therapy. Drug Saf, 35 (12), 1147-1158.
63. Wilton, L., Pearce, G., Edet, E. et al. (1996) The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Br J Urol, 78 (3), 379-384.
64. Wilton, L.V., Mackay, F., Pearce, G., & Mann, R.D. (1997) The outcomes of pregnancy in women prescribed newly marketed drugs in 24 studies con-ducted by prescription-event monitoring (PEM). Pharmacoepidemiol Drug Saf, 6 (Suppl. 2), abstract 072.
65. Wilton, L.V., Stephens, M.D., & Mann, R.D. (1999) Visual field defect associated with vigabatrin: observational cohort study. BMJ, 319 (7218), 1165-1166.
66. Wilton, L.V., Heeley, E.L., Pickering, R.M., & Shakir, S.A. (2001) Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol, 15 (2), 120-126.